EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 janv. 2025 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Provides Company Update and Anticipated Development Milestones for 2025
13 janv. 2025 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of schedule – – Full data for Phase 2...
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors
08 janv. 2025 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference
17 déc. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 déc. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration
04 déc. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– Topline data for Phase 3 pivotal program anticipated in 2026 – WATERTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
18 nov. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments
07 nov. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– Announced positive interim data for DURAVYU 2.7mg in DME demonstrating meaningful, early and sustained visual acuity gains, strong anatomical control and a continued favorable safety profile; BCVA...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
04 nov. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
31 oct. 2024 16h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...